Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy

• Status: Recruiting
• Trial end date: 2025-10-08
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to examine the efficacy and adverse events in the following 3 groups in osteoporosis patients:

1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months.

2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months.

3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shinshu University
• Treatments: Denosumab; Teriparatide

Criteria

Inclusion Criteria:

• Osteoporotic patients who want to take teriparatide and denosumab

Exclusion Criteria:

• Patients who are allergic to teriparatide or denosumab Patients who are pregnant or breast-feedin